Navigating key news stories in pharma

SCHOTT Pharma
All Points of the Pharma Compass

Featured Stories

Featured
Overcoming the Hurdles to Oral Peptide Development
Strategy
Overcoming the Hurdles to Oral Peptide Development
Strategy

Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical workflows designed to bring oral peptides to market safely and predictably.

Read more →
Strategy
News
Navigating the Next Era of RNA Manufacturing
Future Biopharma
Navigating the Next Era of RNA Manufacturing
Future Biopharma

According to Britton Jimenez, from Codexis, the future of RNA therapeutics lies beyond traditional synthesis and requires a shift in manufacturing strategy toward advanced and agile platforms and sourcing.

Read more →
Future Biopharma
ten23 health and dsm firmenich Partner to Expand Excipient Choices for Injectable Biologics
Dealmaking
ten23 health and dsm firmenich Partner to Expand Excipient Choices for Injectable Biologics
Dealmaking

ten23 health and dsm-firmenich have commenced a scientific collaboration to evaluate pharmaceutical-grade ingredients as potential excipients, seeking new materials to address the challenges of formulation stability and manufacturability for parenteral biologic drugs.

Read more →
Dealmaking
Empowering Customer Process Excellence: The Complete Guide to the IMA Active Competence Center E-Learning Academy
Future Biopharma
Empowering Customer Process Excellence: The Complete Guide to the IMA Active Competence Center E-Learning Academy
Future Biopharma

SPONSORED CONTENT: The IMA Active Competence Center Academy is a comprehensive e-learning platform that helps pharmaceutical manufacturers build expertise in solid dose production.

Read more →
Future Biopharma

R&D

Featured
AbbVie Targets Obesity Market with Novel Drug
AbbVie Targets Obesity Market with Novel Drug

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million
NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million

The funding, which is part of a larger investment commitment from the European Commission, will be used to progress Ethris’ differentiated mRNA vaccine technology as a treatment for pandemic flu.

Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA
Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA

The nanoparticle suspension formulation was found to mirror the reference product closely in terms of AUC, Cmax, and Tmax across a 21-day Göttingen minipig study performed by Charles River Laboratories.

Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Expansion

Featured
Cyllene Therapeutics Successfully Raises Millions to Advance Genetic Medicine Candidate
Cyllene Therapeutics Successfully Raises Millions to Advance Genetic Medicine Candidate

The biotech, which was formerly known as EG 427, will use the funds raised in its Series C financing round to advance its lead precision genetic medicine candidate, EG110A.

Codis Announces Three Senior Appointments to Fuel U.S. and European Expansion
Codis Announces Three Senior Appointments to Fuel U.S. and European Expansion

The appointment of three new senior business development directors across Europe and the U.S, will not only strengthen Codis’ commercial team but will also reinforce its commercial capabilities.

Alcami Strengthens Tennessee Site After Tjoapack Acquisition
Alcami Strengthens Tennessee Site After Tjoapack Acquisition

This latest investment by the company combines quality system integration, new high‑speed bottling and expanded cold and ambient storage to support growing U.S. packaging demand.

Curia Enhances Sterile Manufacturing Integrity with Upgraded Aseptic Suites
Curia Enhances Sterile Manufacturing Integrity with Upgraded Aseptic Suites

Ahead of its exhibition at CPHI Americas, Curia announced the completion of its Spanish aseptic upgrades alongside concurrent sterile vial filling and lyophilization expansions underway in Glasgow.

Dealmaking

Featured
ten23 health and dsm firmenich Partner to Expand Excipient Choices for Injectable Biologics
ten23 health and dsm firmenich Partner to Expand Excipient Choices for Injectable Biologics

ten23 health and dsm-firmenich have commenced a scientific collaboration to evaluate pharmaceutical-grade ingredients as potential excipients, seeking new materials to address the challenges of formulation stability and manufacturability for parenteral biologic drugs.

Autolomous and Cellular Origins Target Cell Therapy Scale-Up Challenges with Partnership
Autolomous and Cellular Origins Target Cell Therapy Scale-Up Challenges with Partnership

The integration of Autolomous’ autoloMATE system and Cellular Origins’ Constellation platforms aims to standardize and digitize cell therapy manufacturing within existing bioprocess infrastructure.

Lonza Targets Blood–Brain Barrier Challenge with Nona Biosciences Deal
Lonza Targets Blood–Brain Barrier Challenge with Nona Biosciences Deal

Through acquiring the rights to Nona Biosciences’ TfR1 BBB technology and expanding its strategic collaboration with the company, Lonza is broadening its capabilities to support customers developing next-gen CNS therapies.

Codis Expands Spray Drying Capability Through Catalent Facility Acquisition
Codis Expands Spray Drying Capability Through Catalent Facility Acquisition

The move to acquire Catalent’s Nottingham facility strengthens Codis’ integrated CDMO model, linking formulation, spray drying, and commercial-scale production within a single supply chain.

Strategy

Featured
Overcoming the Hurdles to Oral Peptide Development
Overcoming the Hurdles to Oral Peptide Development

Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical workflows designed to bring oral peptides to market safely and predictably.

Breaking Through the Bitterness Bottleneck
Breaking Through the Bitterness Bottleneck

From highly water-soluble APIs to the strict constraints of personalized therapies, masking unpleasant drug tastes remains a complex engineering challenge, requiring forward-thinking downstream strategies.

Disrupting the Bioprocessing Footprint
Disrupting the Bioprocessing Footprint

With an unprecedented patent cliff looming and complex modalities on the rise, executive teams must decouple capital investment risk from clinical uncertainty by embracing flexible, intensified manufacturing platforms.

BIO 2026: Bridging the Complexity Gap
BIO 2026: Bridging the Complexity Gap

Complex, targeted medicines are introducing bottlenecks into the CMC pathway, creating critical hurdles for clinical scale-up, emphasizes Henny Zijlstra from Ardena.

Future Biopharma

Featured
Navigating the Next Era of RNA Manufacturing
Navigating the Next Era of RNA Manufacturing

According to Britton Jimenez, from Codexis, the future of RNA therapeutics lies beyond traditional synthesis and requires a shift in manufacturing strategy toward advanced and agile platforms and sourcing.

Empowering Customer Process Excellence: The Complete Guide to the IMA Active Competence Center E-Learning Academy
Empowering Customer Process Excellence: The Complete Guide to the IMA Active Competence Center E-Learning Academy

SPONSORED CONTENT: The IMA Active Competence Center Academy is a comprehensive e-learning platform that helps pharmaceutical manufacturers build expertise in solid dose production.

Bridging the Solubility Barrier with Bile Acids
Bridging the Solubility Barrier with Bile Acids

As poor solubility continues to plague development pipelines, alternative biocompatible permeation enhancers are becoming increasingly beneficial for formulation scientists notes Roger Viney from ICE Pharma.

The Pragmatic AI Pivot
The Pragmatic AI Pivot

Recent AI-related news is signaling a shift in the bio/pharma industry’s digital transformation from speculative molecule generation toward grounded biological context and downstream manufacturing execution.

Regulatory

Featured
Weekly HIV Pill Advances Toward Regulatory Submission
Weekly HIV Pill Advances Toward Regulatory Submission

A combination therapy from Gilead and Merck has met its clinical efficacy endpoint, demonstrating non-inferiority to existing daily treatments with no new safety concerns identified in treatment-experienced patient population.

FDA Extends Review of AstraZeneca’s Camizestran
FDA Extends Review of AstraZeneca’s Camizestran

AstraZeneca’s camizestrant has faced a regulatory setback in the U.S., with the FDA extending its review, seeking clearer evidence that early intervention improves long-term outcomes for patients with advanced breast cancer.

First Targeted CSU Therapy for Children Gets Nod from European Commission
First Targeted CSU Therapy for Children Gets Nod from European Commission

The European Commission has approved dupilumab (Dupixent) as the first targeted therapy for chronic spontaneous urticaria (CSU) in children in the EU, broadening its use in type‑2‑driven inflammatory diseases.

Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial

The company has revealed that its humanized, glycoengineered Type II anti-CD20 mAb has achieved superior complete remission rates versus tacrolimus in the MAJESTY study.

Upcoming Events

Featured
Bioprocessing Summit 2026

Now in its 18th year, the Bioprocessing Summit unites a global community of scientists, engineers, and executives driving innovation and digitalization across process development, scale-up, quality, and analytics for biologics, antibodies, cell and gene, RNA, and oligonucleotide therapies.

Lab Ops & Facility Management for Biopharma 2026

The 3rd Lab Ops & Facility Management for Biopharma West Summit will unite 70+ senior lab operations and facilities professionals from leading biotech and pharma organizations to discuss how to run smarter, more resilient laboratories.

Oligonucleotide Analytical Development & CMC Summit 2026

As oligonucleotide therapeutics expand across ASOs, siRNA, gRNA, and increasingly complex conjugates, the field is entering a new phase of clinical and commercial maturity.